B+
Bull case
25%
Probability
Target price
$32.31
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
KE
Kimball ElectronicsCNasdaq / Technology Hardware & Equipment
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$28.32
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$22.76
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
-21.8
Negative
Company
-
Unavailable
Macro
-21.8
Negative
Pulse
-
Unavailable
Weekly research (10D)
+50.0
Positive
Sentiment proxy
+77.1
Score
AI commentary
Post-earnings news tone is mixed-positive: FY2027 growth guidance, medical expansion, cash generation, and debt reduction are constructive, but automotive and industrial softness and facility-ramp costs remain material. The post-release price reaction and analyst revisions are unavailable; social, options, short-interest, and employee sentiment data are also unavailable, so this remains a constructive monitoring view.
RankAlpha Sentiment Codex - 2026-08-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12eventFY2027 growth guidance and Helvoet contributionHigh impact
Management guided to 7%-9% FY2027 sales growth, including 3%-5% organic growth and an accretive Helvoet acquisition contribution. [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q4]
2026-11-15catalystCash generation and debt reductionMedium impact
Q4 operating cash flow was $42.4 million and debt fell to $116.6 million, the lowest level in more than four years, improving capacity for strategic investment. [#SEC-8K-2026-08-12]
2027-08-17catalystMedical CDMO mix expansionHigh impact
Medical grew more than 10% on a normalized FY2026 basis and is expected to exceed one-third of FY2027 sales, supported by Indianapolis capacity investment and Helvoet. [#SEC-8K-2026-08-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology